FBRX — Forte Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1419041 ·
Last close
$43.92
Market Cap
$899.43M
52W High
$45.36
52W Low
$15.51
ADV30
646,194
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,439,000 | -22,136,000 | 67,223,000 | 58,223,000 | 25,123,000 |
| Dec 2025 | 0 | — | -24,571,000 | -24,788,000 | 82,779,000 | 76,957,000 | 21,788,000 |
| Sep 2025 | 0 | — | -18,383,000 | -17,682,000 | 97,089,000 | 93,414,000 | 12,992,000 |
| Jun 2025 | 0 | — | -11,579,000 | -11,249,000 | 107,783,000 | 106,144,000 | 9,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,335,000
Investing CF
$-55,000
Financing CF
$71,757,000
CapEx
$-147,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.56
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,373,000
Inventory
—
Receivables
$817,000
ST Investments
$0
EBIT TTM
$-70,657,000
Pretax Income TTM
$-68,338,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,657,000 | -69,375,000 | 82,779,000 | 21,788,000 | — | -50,882,000 |
| Dec 2024 | 0 | -36,602,000 | -35,478,000 | 61,561,000 | 9,081,000 | — | -30,745,000 |
| Dec 2023 | 0 | -32,486,000 | -31,476,000 | 38,980,000 | 3,666,000 | — | -28,706,000 |
| Dec 2022 | 0 | -13,896,000 | -13,879,000 | 41,997,000 | 3,179,000 | — | -8,185,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.14
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $43.92 · call volume: 56 · put volume: 301Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $898.31M | $6.09 | — |
| TBPH | Theravance Biopharma, Inc. | $877.45M | $16.93 | — |
| ANRO | Alto Neuroscience, Inc. | $929.29M | $26.48 | — |
| LBRX | LB PHARMACEUTICALS INC | $944.90M | $32.95 | — |
| ABUS | Arbutus Biopharma Corp | $948.18M | $4.80 | — |
News headlines (Yahoo Finance, 1h cache)
TRAX Stock Hits All-Time High — What's Driving The Super Rally?
2026-07-10 16:14 · Yahoo
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
2026-07-10 14:18 · Yahoo
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
2026-07-10 14:02 · Yahoo
Forte Biosciences shares surge after positive phase 1b vitiligo results
2026-07-09 17:26 · Yahoo
FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?
2026-07-09 17:06 · Yahoo
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study
2026-07-09 16:26 · Yahoo
Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)
2026-07-09 14:09 · Yahoo
Enovix, Forte Biosciences rally premarket; PepsiCo slips
2026-07-09 13:02 · Yahoo
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
2026-07-09 12:00 · Yahoo
One Forte Biosciences Insider Raised Stake By 30% In Previous Year
2026-06-13 13:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.